Humalog Mix 75/25 is a drug owned by Eli Lilly And Co. It is protected by 4 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 16, 2014. Details of Humalog Mix 75/25's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5474978 | Insulin analog formulations |
Jun, 2014
(10 years ago) |
Expired
|
| US5461031 | Monomeric insulin analog formulations |
Jun, 2014
(10 years ago) |
Expired
|
| US5747642 | Monomeric insulin analog formulations |
Jun, 2014
(10 years ago) |
Expired
|
| US5514646 | Insulin analogs modified at position 29 of the B chain |
May, 2013
(11 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Humalog Mix 75/25 is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Humalog Mix 75/25's family patents as well as insights into ongoing legal events on those patents.
Humalog Mix 75/25's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Humalog Mix 75/25's generic launch date based on the expiry of its last outstanding patent is estimated to be Jun 16, 2014 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Humalog Mix 75/25 Generics:
There are no approved generic versions for Humalog Mix 75/25 as of now.
Alternative Brands for Humalog Mix 75/25
Humalog Mix 75/25 which is used for managing high blood sugar levels in individuals with diabetes mellitus., has several other brand drugs in the same treatment category and using the same active ingredient (Insulin Lispro Protamine Recombinant; Insulin Lispro Recombinant). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Lilly |
| |||||||||
| Sanofi Aventis Us |
| |||||||||
About Humalog Mix 75/25
Humalog Mix 75/25 is a drug owned by Eli Lilly And Co. It is used for managing high blood sugar levels in individuals with diabetes mellitus. Humalog Mix 75/25 uses Insulin Lispro Protamine Recombinant; Insulin Lispro Recombinant as an active ingredient. Humalog Mix 75/25 was launched by Lilly in 1999.
Approval Date:
Humalog Mix 75/25 was approved by FDA for market use on 22 December, 1999.
Active Ingredient:
Humalog Mix 75/25 uses Insulin Lispro Protamine Recombinant; Insulin Lispro Recombinant as the active ingredient. Check out other Drugs and Companies using Insulin Lispro Protamine Recombinant; Insulin Lispro Recombinant ingredient
Treatment:
Humalog Mix 75/25 is used for managing high blood sugar levels in individuals with diabetes mellitus.
Dosage:
Humalog Mix 75/25 is available in injectable form for injection use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 75 UNITS/ML;25 UNITS/ML | INJECTABLE | Prescription | INJECTION |